Cover Image
Market Research Report

EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 626307
Published Content info 77 Pages
Delivery time: 1-2 business days
Price
Back to Top
EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026
Published: April 16, 2018 Content info: 77 Pages
Description

KEY FINDING

Europe Atopic dermatitis drugs market continues to escalate at 3.20% of CAGR over the forecasting years. The deliberated base year for the market study is 2017. The forecasting years are 2018-2026. Increasing focus on systematic therapies and growing awareness among populace are the key factors proliferating the growth of the market in the region.

MARKET INSIGHTS

The developing healthcare infrastructure is one of the major factor augmenting the growth of the market in the region. The various drug class mentioned in the Atopic Dermatitis Drugs market are topical antibiotics, topical antihistamines, topical corticosteroids, topical moisturizers/emollients, topical calcineurin inhibitors, immunomodulators, off-label therapies, systemic agents, PDE-4 inhibitor, and interleukin inhibitor. The region comprises of key countries like UK, France, Russia, Germany and rest of Europe. Among all, UK is the leading country in the region by possessing a colossal share in the market. However, stringent regulations for product approval is one of the major roadblocks of the market to grow in the region.

COMPETITIVE INSIGHTS

Astellas Pharma Inc., Leo Pharma, Allergan Plc, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Aqua Pharmaceuticals (An Almirall Company), Encore Dermatology, Galderma SA, Stiefel Laboratories Inc., Meda Pharmaceuticals (Mylan), Sanofi SA, Astellas Pharma Inc., Novartis Ag, Bayer Ag, Pfizer, and Valent Pharmaceutical Inc. are the dominant organization in the market.

Table of Contents
Product Code: 16694

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY SHARE OF THE OVERALL MARKET
    • 3.2.2. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DYNAMICS

  • 4.1. INTRODUCTION: ATOPIC DERMATITIS
  • 4.2. MARKET DEFINITION & SCOPE
  • 4.3. LEGAL, POLICY AND REGULATORY ISSUES
  • 4.4. MARKET DRIVERS
    • 4.4.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
    • 4.4.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
    • 4.4.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
    • 4.5.2. GENERIC COMPETITION
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
    • 4.6.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
    • 4.6.3. GROWING FOCUS ON NOVEL DRUGS
  • 4.7. MARKET CHALLENGES
    • 4.7.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
    • 4.7.2. HIGHLY GENERCIZED MARKET
    • 4.7.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET BY ROUTE OF ADMINISTRATION (ROA)

  • 5.1. TOPICAL
  • 5.2. ORAL
  • 5.3. INJECTABLE

6. MARKET BY DRUG CLASS

  • 6.1. TOPICAL ANTIBIOTICS
  • 6.2. TOPICAL ANTIHISTAMINES
  • 6.3. TOPICAL CORTICOSTEROIDS
  • 6.4. TOPICAL MOISTURIZERS/EMOLLIENTS
  • 6.5. TOPICAL CALCINEURIN INHIBITORS
  • 6.6. IMMUNOMODULATORS
  • 6.7. OFF-LABEL THERAPIES
  • 6.8. SYSTEMIC AGENTS
  • 6.9. PDE-4 INHIBITOR
  • 6.10. INTERLEUKIN INHIBITOR

7. KEY ANALYTICS

  • 7.1. PORTERS FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. OPPORTUNITY MATRIX
  • 7.3. VENDOR LANDSCAPE
  • 7.4. PIPELINE ANALYSIS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. GERMANY
  • 8.2. FRANCE
  • 8.3. UNITED KINGDOM
  • 8.4. RUSSIA
  • 8.5. REST OF EUROPE

9. COMPANY PROFILES

  • 9.1. ALLERGAN PLC.
  • 9.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
  • 9.3. ASTELLAS PHARMA INC.
  • 9.4. BAYER AG
  • 9.5. BIOFRONTERA AG
  • 9.6. BRISTOL-MYERS SQUIBB
  • 9.7. STIEFEL LABORATORIES INC
  • 9.8. ENCORE DERMATOLOGY
  • 9.9. GALDERMA SA
  • 9.10. LEO PHARMA
  • 9.11. MEDA PHARMACEUTICALS (MYLAN)
  • 9.12. NOVARTIS AG
  • 9.13. PFIZER
  • 9.14. REGENERON PHARMACEUTICALS
  • 9.15. SANOFI SA

LIST OF TABLES

  • TABLE 1: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
  • TABLE 2: REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
  • TABLE 3: RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 4: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2018-2026, (IN $ MILLION)
  • TABLE 5: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2018-2026 (IN $ MILLION)
  • TABLE 6: OPPORTUNITY MATRIX FOR ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 7: VENDOR LANDSCAPE OF ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 8: PIPELINE PORTFOLIO OF ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 9: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: EUROPE ATOPIC DERMATITIS DRUGS MARKET 2018-2026 (IN $ MILLION)
  • FIGURE 2: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ROUTE OF ADMINISTRATION, 2018-2026 (IN $ MILLION)
  • FIGURE 3: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 4: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2017 & 2026 (IN %)
  • FIGURE 5: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL, 2018-2026 (IN $ MILLION)
  • FIGURE 6: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY ORAL, 2018-2026 (IN $ MILLION)
  • FIGURE 7: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY INJECTABLE, 2018-2026 (IN $ MILLION)
  • FIGURE 8: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2017 & 2026 (IN %)
  • FIGURE 9: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIBIOTICS, 2018-2026 (IN $ MILLION)
  • FIGURE 10: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIHISTAMINES, 2018-2026 (IN $ MILLION)
  • FIGURE 11: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CORTICOSTEROIDS, 2018-2026 (IN $ MILLION)
  • FIGURE 12: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL MOISTURIZERS/EMOLLIENTS, 2018-2026 (IN $ MILLION)
  • FIGURE 13: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CALCINEURIN INHIBITORS, 2018-2026 (IN $ MILLION)
  • FIGURE 14: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY IMMUNOMODULATORS, 2018-2026 (IN $ MILLION)
  • FIGURE 15: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY OFF-LABEL THERAPIES, 2018-2026 (IN $ MILLION)
  • FIGURE 16: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY SYSTEMIC AGENTS, 2018-2026 (IN $ MILLION)
  • FIGURE 17: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY PDE-4 INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 18: EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
  • FIGURE 19: PORTER'S FIVE FORCE MODEL OF ATOPIC DERMATITIS DRUGS MARKET
  • FIGURE 20: EUROPE ATOPIC DERMATITIS DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
  • FIGURE 21: GERMANY ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 22: FRANCE ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 23: UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 24: RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 25: REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
Back to Top